NovaBay Pharmaceuticals, Inc.
NBY · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.04 |
| FCF Yield | -254.24% | -484.36% | -330.44% | -63.34% |
| EV / EBITDA | -0.55 | -0.10 | 0.18 | -0.87 |
| Quality | ||||
| ROIC | -378.42% | -78.32% | -37.72% | -8.74% |
| Gross Margin | 66.26% | 58.19% | 54.02% | 67.03% |
| Cash Conversion Ratio | 0.72 | 0.69 | 0.63 | 1.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.10% | 0.81% | 13.18% | 15.64% |
| Free Cash Flow Growth | -25.04% | 38.66% | 26.81% | -94.73% |
| Safety | ||||
| Net Debt / EBITDA | -0.21 | 0.08 | 0.46 | 0.80 |
| Interest Coverage | -6.46 | -2.95 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.31 | 1.52 | 1.93 | 0.86 |
| Cash Conversion Cycle | 30.22 | 172.38 | 179.89 | 358.28 |